Actively Recruiting
Diagnosing Drug Allergy: the T is the Key
Led by University Hospital, Antwerp · Updated on 2026-05-14
300
Participants Needed
1
Research Sites
175 weeks
Total Duration
On this page
Sponsors
U
University Hospital, Antwerp
Lead Sponsor
A
AZ Jan Palfijn Gent
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trial is to validate a newly developed test in the diagnosis of patients with amoxicillin allergy (i.e. T-cell activation test). The main questions the study aims to assess are the reliability and applicability of this test. Participants will be asked to visit the hospital 1, 3 or 5 times during which blood is collected and when applicable, allergy skin testing is performed.
CONDITIONS
Official Title
Diagnosing Drug Allergy: the T is the Key
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants aged 6 years or older
- Able to provide informed consent or have a parent/guardian provide consent if under 18
- Have a suspected history of amoxicillin allergy
You will not qualify if you...
- Unable to provide informed consent and no acceptable individual to consent on their behalf
- Pregnant women
- Breastfeeding women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Antwerp University Hospital
Edegem, Antwerp, Belgium, 2650
Actively Recruiting
Research Team
D
Didier Ebo, PhD
CONTACT
L
Laura Peeters, Msc
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here